Le Lézard
Classified in: Health, Business
Subjects: CXP, MAT

Cansortium Announces Opening of its Newest Fluenttm Medical Marijuana Dispensary in Fort Myers, Florida


MIAMI, July 17, 2019 /PRNewswire/ - Cansortium Inc. ("Cansortium" or the "Company") (CSE: TIUM), a vertically-integrated, global provider of premium-quality medical cannabis operating under the Fluenttm brand, continues to expand its Florida retail footprint with the July 15th opening of a new Fluent dispensary in a prime location in Fort Myers, FL. The new 1,600 square-foot dispensary, located at 5611 Six Mile Commercial Court in the Marlins Plaza shopping center, is the Company's thirteenth in Florida, with seventeen more locations expected to be opened or secured by the end of 2019. The Company's dispensaries carry a complete assortment of Fluent premium dried flower, and full spectrum concentrates and cartridges as well as creams, drops, capsules and suppositories.

Cansortium Inc. (CNW Group/Cansortium Inc)

Cansortium's Chief Executive Officer Jose Hidalgo noted, "Our new Fluent dispensary in Fort Myers is our first in southwest Florida and is strategically located to provide access to Lee, Charlotte and Collier counties, which do not currently allow dispensaries, as well as to the neighboring city of Estero, which does not yet have a dispensary within its city limits."

Mr. Hidalgo continued, "Cansortium's expanding dispensary network is enhancing access to our premium-quality Fluent cannabis products for medical marijuana patients across Florida - the state with the fastest-growing medical marijuana patient population in the U.S. Our Fluent brand continues to strive to set the standard for premium-quality, consistently formulated cannabis products cultivated, processed and packaged in our state-of-the-art Florida facilities in strict compliance with Florida regulations. For consumers, our sleek, modern Fluent dispensaries provide a warm, welcoming, professional environment, with knowledgeable staff who carefully guide patients in selecting the right products and who understand the importance of safeguarding patient privacy."

ABOUT CANSORTIUM INC.
Cansortium is a global medical cannabis company operating in highly populous medical cannabis markets with a mission to deliver the highest standards of cannabis care from nursery to lab to shelf. Headquartered in Miami, FL and operating under the recently-launched Fluenttm brand (formerly Knox Medical), the Company through its subsidiaries operates cultivation, processing and dispensary facilities across Florida, Texas, Puerto Rico and a dispensary license in Pennsylvania. The Company also has licensed cultivation facilities in Colombia and Canada, with licensing pending in Michigan.

Cansortium Inc.'s common shares and warrants trade on the CSE under the symbol "TIUM.U" and "TIUM.WT.U" respectively.

Forward-Looking Information

Certain information in this news release, may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For information on Cansortium Inc., please visit www.cansortium.com.

Fluent Cannabis Care is the Brand for Cansortium Inc. (CNW Group/Cansortium Inc)

SOURCE Cansortium Inc


These press releases may also interest you

at 17:35
MaaT Pharma announced today that leading hemato-oncological experts presented clinical data on the compassionate use of MaaT Pharma's lead full-ecosystem microbiome restoration biotherapeutic, MaaT013. The data included eight patients that developed...

at 17:35
Magenta Therapeutics , a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its MGTA-145 stem cell mobilization program were presented at...

at 16:05
The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data analyses reporting outcomes on the safety and effectiveness of Eliquis® (apixaban) compared to low molecular weight heparin (LMWH) or warfarin for the...

at 14:30
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Baxter International Inc. between February 21, 2019 and October 23, 2019, inclusive (the "Class Period") of the important January 24, 2020 lead plaintiff...

at 14:05
Kite, a Gilead Company , today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2...

at 14:05
bluebird bio, Inc. announced new data from its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobintm gene therapy for sickle cell disease (SCD), including additional patients treated in the study and updated data for those previously...



News published on 17 july 2019 at 09:00 and distributed by: